Agenda

Accreditation Partner

Welcome Day

Thursday, APRIL 18, 2024

ACL Live, Keller Pfluger Gallery – Mezzanine Level, 2nd floor

6:00 PM - 9:00 PM

Day One

Friday, APRIL 19, 2024

7:30 AM – 8:20 AM at the W Hotel, Great Room 

8:40 AM  Stage III Unresectable

8:50 AM  PD-(L)1 Monotherapy for NSCLC

9:00 AM  Chemotherapy + PD-(L)1 for NSCLC

9:10 AM  PD-(L)1 + CTLA4 +/- Chemotherapy

9:20 AM  Antibody Drug Conjugates + IO Combinations in NSCLC

9:30 AM  Case Study

9:40 AM  Q&A

10:00 AM – 10:30 AM  ACL Live, Music Porch and W Hotel, Prefunction Hall

10:30 AM  Limited Stage SCLC

10:40 AM  1L Extensive Stage SCLC

10:50 AM  2L+ SCLC

11:00 AM  SCLC Biomarkers

11:10 AM  Mesothelioma

11:20 AM  Thymic Malignancies

11:30 AM  Case Study

11:40 AM  Q&A

12:10 AM – 1:40 PM  W Hotel, Great Room

1:40 PM  Biomarkers: What is NGS?

1:50 PM  1L EGFR

2:00 PM  EGFR Exon 20 and Atypical Mutations

2:10 PM  Overcoming EGFR TKI Resistance

2:20 PM  HER2 in NSCLC

2:30 PM  MET for NSCLC: TKI and ADC

2:40 PM  Case Study

2:50 PM  Q&A

3:10 PM – 3:40 PM  ACL Live, Music Porch and W Hotel, Prefunction Hall

3:40 PM  Liquid Biopsy in Lung Cancer

3:50 PM  Artificial Intelligence in Lung Cancer

4:00 PM  Translating Biomarkers to Better Outcomes in NSCLC

4:10 PM  TTFields for the Thoracic Oncologist

4:20 PM  Social Media for the Practicing Oncologist

4:30 PM  Evolving Partnership with Patient Advocacy

4:40 PM  Health Care Policy for Today’s Oncologist

4:50 PM  Q&A

5:10 PM – 6:00 PM  at ACL Live, General Session

Day Two

Saturday, April 20, 2024

7:30 AM – 8:20 AM at the W Hotel, Great Room 

8:30 AM  Duration of IO Therapy for Advanced NSCLC

8:40 AM  Rechallenge with IO in NSCLC

8:50 AM  Managing Brain Metastases in NSCLC

9:00 AM  Toxicity and Contraindications for IO in NSCLC

9:10 AM  IO and Targeted Therapy in NSCLC: Sequence, Toxicity

9:20 AM  Biomarker Selection (STK11, KEAP1, PDL1) for IO in NSCLC

9:30 AM  Case Study

9:40 AM  Q&A

10:00 AM – 10:30 AM  ACL Live, Music Porch and W Hotel, Prefunction Hall

10:30 AM  ALK

10:40 AM  ROS1/RET/NTRK/NRG1

10:50 AM  BRAF

11:00 AM  KRAS G12C

11:10 AM  Antibody Drug Conjugates

11:20 AM  Case Study

11:30 AM  Q&A

11:50 AM – 1:30 PM  W Hotel, Great Room

1:30 PM  Targeted Perioperative Therapy for Early-Stage NSCLC

1:40 PM  Adjuvant IO Therapy for NSCLC

1:50 PM  Neoadjuvant IO Therapy for NSCLC

2:00 PM  Perioperative IO Therapy for NSCLC

2:10 PM  Case Study

2:20 PM  Q&A

2:50 PM – 3:00 PM  ACL Live, Music Porch and W Hotel, Prefunction Hall

3:00 PM  Impact of Adjuvant after Neoadjuvant

3:10 PM  Surgical Implications of Neoadjuvant Therapy for NSCLC

3:20 PM  Selection of Endpoints: Impact on Practice

3:30 PM  Q&A

3:40 PM  Perioperative Chemo+IO IS Superior To (Neo)Adjuvant Therapy In Early-Stage NSCLC

3:50 PM  Perioperative Chemo+IO IS NOT Superior To (Neo)Adjuvant Therapy In Early-Stage NSCLC

ACL Live, Keller Pfluger Gallery – Mezzanine Level, 2nd floor

7:00 PM - 9:00 PM

Join #TexasLung24 in Austin, Texas

Come for the education.